Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Apostolidis, Apostolos  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Apostolidis, A., Kirana P-S., Chiu G., Link C., Tsiouprou M., & Hatzichristou D. (2009).  Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study.. Eur Urol. 56(6), 937-47.
Apostolidis, A., Wagg A., A'i M. S. Rahnam, Panicker J. N., Vrijens D., & von Gontard A. (2018).  Is there "brain OAB" and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017.. Neurourol Urodyn. 37(S4), S38-S45.
Apostolidis, A. (2015).  Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?. Curr Drug Targets. 16(11), 1187-97.
Apostolidis, A. (2019).  Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?. World J Urol. 37(12), 2811-2812.
Apostolidis, A. (2017).  Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?. BJU Int. 120(4), 459-460.
Apostolidis, A. (2015).  Words of wisdom. Re: Intrathecal administration of botulinum toxin type a improves urinary bladder function and reduces pain in rats with cystitis.. Eur Urol. 67(4), 816.
Apostolidis, A., & Cameron A. P. (2020).  Neurourological Management After Failed Intradetrusor OnabotulinumtoxinA Injections.. Eur Urol Focus. 6(5), 814-816.
Apostolidis, A., Averbeck M. Augusto, Sahai A., Rahnama'i M. Sajjad, Anding R., Robinson D., et al. (2017).  Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).. Neurourol Urodyn. 36(4), 882-893.
Apostolidis, A. (2013).  Male lower urinary tract symptoms: a riddle waiting to be solved.. Eur Urol. 64(3), 408-10.
Apostolidis, A., Papaefstathiou E., & Gatsos S. (2020).  Intravesical Botox for overactive bladder; how to minimize complications and manage failures.. Curr Drug Targets.
Apostolidis, A., Rantell A., Anding R., Kirschner-Hermanns R., & Cardozo L. (2017).  How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2.. Neurourol Urodyn. 36(4), 869-875.
Apostolidis, A., Thompson C., Yan X., & Mourad S. (2013).  An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.. World J Urol. 31(6), 1469-74.
Apostolidis, A., Papaefstathiou E., & Gatsos S. (2020).  Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures. Current Drug Targets. 21(15), 1527 - 1536.
Apostolidis, A., Rahnama'i M. S., Fry C., Dmochowski R., & Sahai A. (2016).  Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.. Neurourol Urodyn. 35(2), 293-8.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές